 of the patient's own immune system so that their own immune system kills those small cell lung cancer cells. Now, I mentioned, Laura, that on average, patients will survive with extensive stage small cell lung cancer for between three and five months after they're diagnosed. We were thrilled with the results of this clinical trial because we found that Imdeltra use was essentially able to triple that survival out to 14 months.